Association of coagulopathy with liver dysfunction in patients with COVID-19.

Abstract

AimLiver dysfunction is sometimes observed in patients with coronavirus disease 2019 (COVID‐19), but most studies are from China, and the frequency in other countries is unclear. In addition, previous studies suggested several mechanisms of liver damage, but precise or additional mechanisms are not clearly elucidated. Therefore, we examined COVID‐19 patients to explore the proportion of patients with liver dysfunction and also the factors associated with liver dysfunction.MethodsWe retrospectively examined 60 COVID‐19 patients hospitalized at the Hospital affiliated with The Institute of Medical Science, The University of Tokyo (Tokyo, Japan). Patients who presented ≥40 U/L alanine aminotransferase (ALT) levels at least once during their hospitalization were defined as high‐ALT patients, and the others as normal‐ALT patients. The worst values of physical and laboratory findings during hospitalization for each patient were extracted for the analyses. Univariable and multivariable logistic regression models with bootstrap (for 1000 times) were carried out.ResultsAmong 60 patients, there were 31 (52%) high‐ALT patients. The high‐ALT patients were obese, and had significantly higher levels of D‐dimer and fibrin/fibrinogen degradation products, as well as white blood cell count, and levels of C‐reactive protein, ferritin, and fibrinogen. Multivariable analysis showed D‐dimer and white blood cells as independent factors.ConclusionsConsidering that higher D‐dimer level and white blood cell count were independently associated with ALT elevation, liver dysfunction in COVID‐19 patients might be induced by microvascular thrombosis in addition to systemic inflammation.